Elanco Animal HealthELAN
ELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,450
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 125
4% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $10.8M
0.86% more ownership
Funds ownership: 98.98% [Q4 2024] → 99.84% (+0.86%) [Q1 2025]
8% less funds holding
Funds holding: 386 [Q4 2024] → 356 (-30) [Q1 2025]
12% less capital invested
Capital invested by funds: $5.93B [Q4 2024] → $5.19B (-$740M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
37% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 70
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
16%
upside
Avg. target
$16
16%
upside
High target
$16
16%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Stifel Jonathan Block | 16%upside $16 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Based on 7 articles about ELAN published over the past 30 days
Neutral
PRNewsWire
2 days ago
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days.
Positive
Zacks Investment Research
4 days ago
What Makes Elanco Animal Health (ELAN) a New Buy Stock
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
4 days ago
ELAN vs. USPH: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
Neutral
Zacks Investment Research
5 days ago
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.
Neutral
PRNewsWire
1 week ago
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1 Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1 Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1 Leading veterinarians and canine dermatologists, including Drs.
Neutral
PRNewsWire
2 weeks ago
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
GREENFIELD, Ind. , May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.
Neutral
PRNewsWire
4 weeks ago
Elanco to Participate in the Upcoming Investor Conferences
GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
Neutral
Seeking Alpha
1 month ago
Elanco: Deleveraging Takes Time
Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring Bayer's animal health business. Despite some sales growth and debt reduction efforts, EBITDA and earnings are declining, limiting enthusiasm for significant investment.
Neutral
Seeking Alpha
1 month ago
Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Andrea Alfonso - UBS Brandon Vazquez - William Blair Ekaterina Knyazkova - JPMorgan Navann Ty - BNP Paribas Mike DiFiore - Evercore ISI Erin Wright - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health First Quarter 2025 Earnings Conference Call.
Neutral
Benzinga
1 month ago
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco Animal Health Incorporated ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.
Charts implemented using Lightweight Charts™